0001725160-24-000034.txt : 20240205
0001725160-24-000034.hdr.sgml : 20240205
20240205191534
ACCESSION NUMBER: 0001725160-24-000034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240205
DATE AS OF CHANGE: 20240205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lackner Mark
CENTRAL INDEX KEY: 0001777413
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39263
FILM NUMBER: 24597537
MAIL ADDRESS:
STREET 1: C/O IDEAYA BIOSCIENCES, INC.
STREET 2: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001725160
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 823607803
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 801
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: (212) 433-3791
MAIL ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 801
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20200107
FORMER COMPANY:
FORMER CONFORMED NAME: Zeno Pharma, LLC
DATE OF NAME CHANGE: 20171212
4
1
wk-form4_1707178516.xml
FORM 4
X0508
4
2024-02-01
0
0001725160
Zentalis Pharmaceuticals, Inc.
ZNTL
0001777413
Lackner Mark
C/O ZENTALIS PHARMACEUTICALS, INC.
1359 BROADWAY, SUITE 801
NEW YORK
NY
10018
0
1
0
0
Chief Scientific Officer
0
Common Stock
2024-02-01
4
A
0
141000
0
A
197313
D
Common Stock
2024-02-02
4
S
0
1585
11.54
D
195728
D
Stock Option (Right to Buy)
11.69
2024-02-01
4
A
0
141000
0
A
2034-01-31
Common Stock
141000
141000
D
Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. The options are Reporting Person's annual equity grants, which reflect the market data for Reporting Person's role as Chief Scientific Officer, a role to which he was promoted on December 31, 2023.
/s/ Andrea Paul, attorney-in-fact for Mark Lackner
2024-02-05